• SAB Biotherapeutics outlined plans to present additional clinical and mechanistic data on SAB-142, its lead immunotherapy program for newly diagnosed Stage 3 type 1 diabetes, at Immunology of Diabetes Society Congress in Brisbane on April 20-24, 2026.
• Results will be presented in future sessions, including an oral presentation on April 22, 2026, with poster presentations scheduled for April 21-22, 2026.
• Data focus on SAB-142’s multi-target binding profile and updated evidence supporting preservation of insulin-producing cell function, reinforcing positioning as a potentially best-in-class, repeat-dosing, disease-modifying therapy.
• Company flagged SAFEGUARD study is actively enrolling, with topline results expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150800PRIMZONEFULLFEED9689742) on April 15, 2026, and is solely responsible for the information contained therein.